Loading stock data…
LUNG
$1.35+0.07 (+5.47%)
Market ClosedLast close May 1
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pulmonx Corporation in the Healthcare sector is trading at $1.35. The stock is currently near its 52-week low of $1.13, remaining 23.7% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why LUNG maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.35
Potential Upside
5%
Whystock Fair Value$1.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$5.17+282.7%
Range$2.50 – $14.00
Fundamentals
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pul...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-99.79%
Volume
Today's trading volume
1.08M
Recent News
Pulmonx (LUNG) Q1 2026 Earnings Transcript
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.
Pulmonx Corporation Q1 2026 Earnings Call Summary
Moby summary of Pulmonx Corporation's Q1 2026 earnings call
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
Pulmonx Corp (LUNG) demonstrates resilience with operational momentum and strategic expansion despite revenue challenges.
Pulmonx Q1 Earnings Call Highlights
Pulmonx (NASDAQ:LUNG) reported first-quarter 2026 worldwide revenue of $20.6 million, as management emphasized early progress on commercial execution, continued advancement of its AeriSeal clinical program, and actions to reduce spending and extend its cash runway. Executives reiterated full-year 20
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of 0.00% and +2.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?